Kisqali has shown to improve survival in advanced breast cancer; Ibrance has not. While early data had indicated a medicine ...

Among patients with ER-positive/HER2-negative advanced breast cancer, treatment with camizestrant in combination with Kisqali ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of ...

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...

Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that underscore the extended efficacy beyond the duration of treatment in ...

a population that represents 10% of breast cancer patients. Although not a game-changer for Pfizer, the data could could help ...

B reast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s ...

Patients included in the trial had HR+/HER2– metastatic breast cancer, were 18 years or older, and started index treatment ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

DCIS, known as stage 0 breast cancer, affect the cells lining the milk ducts but has not spread outside the breast.